-
Review Article
-
J Korean Neurol Assoc. 2026;44(2):124-133. Published online May 1, 2026.
DOI: https://doi.org/10.17340/jkna.2025.0062
- Therapeutic Paradigm Changes in Myasthenia Gravis and Amyotrophic Lateral Sclerosis
-
Seong-il Oh
-
Department of Neurology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea
- 중증근무력증과 근위축측삭경화증에서의 치료 패러다임 전환
-
오성일
-
- Corresponding author: Seong-il Oh ,Tel: +82-2-958-8499, Fax: +82-2-958-8490, Email: ohsi@khu.ac.kr
- Received: December 30, 2025; Revised: February 27, 2026 Accepted: March 3, 2026.
- Abstract
- The treatment paradigm for neuromuscular diseases, especially myasthenia gravis and amyotrophic lateral sclerosis, has recently shifted with the emergence of mechanism-based and precision therapies. In myasthenia gravis, improved understanding of antibody-mediated pathology has enabled the clinical adoption of targeted immunotherapies, including complement inhibitors and neonatal Fc receptor antagonists, resulting in meaningful benefits for refractory disease and a shift beyond conventional immunosuppression. In amyotrophic lateral sclerosis, while multidisciplinary care remains fundamental, recent advances highlight a gradual move toward precision medicine through platform trial designs, biomarker-informed evaluation, and gene-specific molecular therapies for selected patient subgroups. Together, these developments reflect a paradigm shift from uniform treatment strategies to individualized, pathophysiology-driven clinical decision-making. This review summarizes recent guideline updates and key clinical trial evidence, illustrating how advances in immunopathology, genetics, and trial methodology are redefining contemporary neuromuscular care.
Keywords :Neuromuscular diseases, Myasthenia gravis, Amyotrophic lateral sclerosis, Precision medicine, Targeted immunotherapy
- 초록
-
